- RecruitingPHASE3
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
This study looks at new drug combinations for advanced breast cancer. It compares saruparib and camizestrant with common existing treatments to see which works best for people with specific genetic changes (BRCA1, BRCA2, or PALB2m) in their cancer.
For: Advanced Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
This study is testing a new combination of medicines, Giredestrant and Palbociclib, for advanced breast cancer. It's for people whose cancer is hormone-sensitive (ER-positive) but not HER2-positive. Researchers want to see if this new combination works better and is safer than a standard treatment.
For: Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerUnited States · Argentina · Australia - RecruitingPHASE2
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
This study is looking at new treatments for early-stage breast cancer. It focuses on a specific type of breast cancer (ER-positive, HER2-negative) that has a particular gene change (PIK3CA mutation). Researchers want to see how safe and effective the new medicine, Inavolisib, is when combined with other known treatments.
For: Breast CancerUnited States · Argentina · Brazil - RecruitingPHASE3
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
This study is looking at a new combination of medicines for a certain type of advanced breast cancer. It compares a new drug, inavolisib, with existing treatments to see if it's more effective and safe for people whose cancer has a specific genetic change (PIK3CA mutation).
For: Breast CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
This study is for people with advanced breast cancer that has a specific genetic change (PIK3CA). It's testing a new drug, Tersolisib, alongside other cancer medicines, to see if it's safe and helps treat the disease effectively.
For: Breast Neoplasms · Neoplasm MetastasisUnited States · Argentina · Australia - Active not recruitingPHASE3
Detect V / CHEVENDO (Chemo vs. Endo)
This study compares different treatments for advanced breast cancer that has spread. It aims to see if a combination of targeted therapies and hormone therapy works better than targeted therapies and chemotherapy, while also keeping quality of life high.
For: Metastatic Breast CancerGermany - Active not recruitingPHASE3
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
This study compares a new medicine called palazestrant with standard treatments for advanced breast cancer that has grown despite previous hormone therapy. It's for men and women whose cancer is ER-positive and HER2-negative.
For: Breast Cancer · Advanced Breast Cancer · Metastatic Breast CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
This study looks at a new drug combination, avutometinib and defactinib, for low-grade serous ovarian cancer that has come back. It compares this new treatment to standard options to see which works best and is safest for patients.
For: Low Grade Serous Ovarian CancerUnited States · Australia · Belgium - RecruitingPHASE2
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
This study is testing a new medicine, MK-5684, for breast, ovarian, and endometrial cancers. It aims to see if MK-5684, which blocks steroid hormones, can stop cancer from growing or spreading for longer than current standard treatments.
For: Malignant NeoplasmUnited States · Argentina · Brazil - RecruitingPHASE3
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
This study looks at a new drug, palazestrant, combined with standard treatment (ribociclib) for advanced breast cancer that is ER-positive and HER2-negative. It compares this new combination to the standard treatment alone to see if it works better and is safe for people who haven't had other treatments for their advanced cancer.
For: Breast Cancer · Locally Advanced Breast Cancer · Metastatic Breast CancerUnited States · Australia · Austria - RecruitingPHASE1, PHASE2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
This study looks at different treatment combinations for advanced breast cancer, including those that have spread or are hard to remove. Doctors want to see how well these new drug combinations work and if they are safe for patients.
For: Metastatic Breast CancerUnited States · Australia · France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Clinical and endocrinological effects of letrozole during the luteal phase after controlled ovarian stimulation in oocyte donors: a low interventional, randomized, controlled trial
This study looks at how a medicine called letrozole, given after ovarian stimulation, affects the ovaries in women who donate eggs. Researchers want to see if it changes the size of the ovaries and other body chemicals, helping us understand its safety and effectiveness.
For: Female InfertilitySpain - Active not recruitingPHASE3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
This study is looking at a new drug, camizestrant, for people with a common type of early breast cancer. It aims to see if camizestrant, compared to usual hormone therapy, can better prevent the cancer from coming back.
For: Breast Cancer, Early Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE2
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
This study is looking at new treatments for a specific type of ovarian cancer that has come back or won't go away. We want to see if these treatments are safe and effective for patients whose cancer has certain genetic features.
For: Ovarian CancerUnited States · Australia · Canada - Active not recruitingPHASE3
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
This study is testing a new drug, AZD9833, for advanced breast cancer. It's for people whose cancer has a specific gene change (ESR1 mutation) and are already on certain treatments. Researchers want to see if adding AZD9833 works better than current medicines.
For: ER-Positive HER2-Negative Breast CancerUnited States · Australia · Austria - RecruitingPHASE3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
This study is testing a new drug, Elacestrant, against standard hormone treatments for early breast cancer. It's for men and women whose cancer is ER-positive and HER2-negative, and has a high chance of coming back. The aim is to see if Elacestrant works better.
For: Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE2
Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.
This study looks at new ways to treat a type of breast cancer called HER2-positive. We're testing if using special drugs (Herceptin and Perjeta) without chemotherapy first can shrink tumours effectively. We're also checking if scans can predict how well treatments work.
For: Breast CancerBelgium · France · Germany - Active not recruitingPHASE1
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
This study looks at a new drug, Inavolisib, for people with solid tumours or breast cancer, focusing on safety and how the body handles it. It's an early-stage study, checking if the drug works alone or with other common cancer treatments.
For: Breast Cancer · Solid TumorUnited States · Canada · France - Active not recruitingPHASE2
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
This study is testing a new drug, PF-07220060, for people with advanced cancers like breast, prostate, and lung cancer. Researchers want to see if it's safe and how it works, both by itself and with other cancer medicines.
For: Liposarcoma · Prostate Cancer · Breast NeoplasmsUnited States · Argentina · China - Active not recruitingPHASE1, PHASE2
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
This study looks at new drug combinations for advanced ER+ breast cancer in women aged 18-100. It tests LEE011 and BYL719 with letrozole to find safe and effective doses, hoping to improve treatment for this type of cancer.
For: Breast CancerUnited States · Australia · France - RecruitingPHASE3
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
This study looks at a new medicine called BGB-43395 combined with letrozole for advanced breast cancer. It compares this new combination to standard treatments (other CDK4/6 inhibitors plus letrozole) for people who haven't had previous treatment for their advanced cancer.
For: HR+/HER2- Breast CancerUnited States · Australia · China - RecruitingPHASE2
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
This study looks for tiny traces of cancer DNA in the blood to find early signs of breast cancer coming back. If found, it tests if a new treatment combination (Palbociclib and Fulvestrant) works better than standard treatment for ER-positive, HER2-negative breast cancer.
For: ER+ Breast Cancer · HER2-negative Breast CancerFrance · United Kingdom - Active not recruitingPHASE3
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
This study looks at a new combination of medicines for postmenopausal women with a certain type of breast cancer. It tests if abemaciclib with standard hormone therapy works better than hormone therapy alone.
For: Breast CancerUnited States · Australia · Austria - RecruitingPHASE3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
This study is testing a new drug, camizestrant, for early breast cancer that's hormone-sensitive. We want to see if it works better than standard hormone therapy in reducing the risk of cancer coming back, for people who have already had initial treatment.
For: Breast Cancer, Early Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
This study looks at the best treatment for women with a common type of early breast cancer. It compares hormone therapy alone against hormone therapy plus chemotherapy, using a special test to help decide which is best for each woman.
For: Breast Adenocarcinoma · Hormone Receptor Positive · Stage IA Breast Cancer AJCC v7United States · Australia · Canada - Active not recruitingPHASE3
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
This study looks at a new drug, imlunestrant, for early breast cancer. It compares it to standard hormone treatments like tamoxifen, anastrozole, letrozole, and exemestane. The goal is to see if imlunestrant works better for patients whose cancer is at higher risk of returning.
For: Breast NeoplasmsUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
This study is looking at a new drug, PF-07220060, combined with letrozole for advanced breast cancer. It compares this new treatment to existing approved therapies to see if it's safe and works well for people whose cancer needs hormones to grow.
For: Breast CancerUnited States · Argentina · Australia - AuthorisedTherapeutic confirmatory (Phase III)
A phase III study comparing the concurrent versus the sequential administration of chemotherapy and aromatase inhibitors, as adjuvant treatment of post-menopausal patients with endocrine-responsive early breast cancer
This study is for women who have gone through menopause and have an early type of breast cancer that responds to hormones. Researchers are looking at the best way to give two important treatments: chemotherapy and hormone therapy. They want to see if giving them at the same time or one after the other is better.
For: Breast cancer is the most common form of cancer among women in North America · Europe and Latin America. Beacause nearly 80% of breast cancers are endocrine-responsive tumorsItaly